Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- Budget 2025: India Inc shares crucial expectations from FM Nirmala Sitharaman
- Incentives for R&D: New foreign trade policy to retain key schemes despite WTO trouble
- New regime may benefit India on oil, Ukraine deal
- Cooking gas price hiked by Rs11.50 per cylinder as India starts to lose advantage of low oil prices
